SURMOUNT-1
The pivotal Phase 3 trials and post-approval cardiovascular, kidney, and sleep-apnea outcome studies.
Definition
Pivotal Phase 3 trial of tirzepatide 5/10/15 mg weekly vs placebo in 2,539 adults with overweight/obesity (Jastreboff et al, NEJM 2022, PMID 35658024). Mean weight loss 20.9% at 15 mg over 72 weeks.
Tirzepatide vs semaglutide head-to-head →
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Major trials
Looking for more depth?
- Tirzepatide vs semaglutide head-to-head
- Browse the full GLP-1 glossary (51 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers